Global Antibiotic R&D Partnership (Gardp)

Global Antibiotic R&D Partnership (Gardp) company information, Employees & Contact Information

The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org

Company Details

Employees
102
Founded
-
Address
Chemin Louis-Dunant 15, Geneva,switzerland 1202,switzerland
Phone
+41 22 907 76 11
Email
ga****@****ndi.org
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Website
gardp.org
HQ
Geneva, Switzerland
Looking for a particular Global Antibiotic R&D Partnership (Gardp) employee's phone or email?

Global Antibiotic R&d Partnership (Gardp) Questions

News

Catalyzing Change: Entrepreneurs from the Global South Leading the Fight against Antimicrobial Resistance - ACS Publications

Catalyzing Change: Entrepreneurs from the Global South Leading the Fight against Antimicrobial Resistance ACS Publications

FDA accepts new drug application for zoliflodacin for uncomplicated gonorrhea - Urology Times

FDA accepts new drug application for zoliflodacin for uncomplicated gonorrhea Urology Times

Most people with highly drug-resistant infections are not accessing appropriate treatment - Gavi, the Vaccine Alliance

Most people with highly drug-resistant infections are not accessing appropriate treatment Gavi, the Vaccine Alliance

Most drug-resistant infections go untreated in India, study finds - Nature

Most drug-resistant infections go untreated in India, study finds Nature

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults - FinancialContent

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults FinancialContent

PAHO and GARDP will collaborate to tackle antibiotic resistance in Latin America and the Caribbean - Pan American Health Organization (PAHO)

PAHO and GARDP will collaborate to tackle antibiotic resistance in Latin America and the Caribbean Pan American Health Organization (PAHO)

Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries - Clinton Health Access Initiative

Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries Clinton Health Access Initiative

Prevalence and determinants of neonatal infections in Benin based on a retrospective study in six reference hospitals - Nature

Prevalence and determinants of neonatal infections in Benin based on a retrospective study in six reference hospitals Nature

WHO charts roadmap to combat antibiotic shortages in low- and middle-income countries - Down To Earth

WHO charts roadmap to combat antibiotic shortages in low- and middle-income countries Down To Earth

Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance - The Lancet

Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance The Lancet

Next-Generation Approaches Needed to Tackle Antimicrobial Resistance for the Development of Novel Therapies Against the Deadly Pathogens - Frontiers

Next-Generation Approaches Needed to Tackle Antimicrobial Resistance for the Development of Novel Therapies Against the Deadly Pathogens Frontiers

GARDP, Bugworks to collaborate on broad-spectrum antibiotic - CIDRAP

GARDP, Bugworks to collaborate on broad-spectrum antibiotic CIDRAP

Learning from COVID-19 to Tackle Antibiotic Resistance - ACS Publications

Learning from COVID-19 to Tackle Antibiotic Resistance ACS Publications

Addressing the overlooked frontier in AMR research and surveillance - Frontiers

Addressing the overlooked frontier in AMR research and surveillance Frontiers

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae - eBioMedicine - The Lancet

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae - eBioMedicine The Lancet

GARDP and CHAI seek requests for proposals (RfPs) to manufacture cefiderocol to treat bacterial infections - Clinton Health Access Initiative

GARDP and CHAI seek requests for proposals (RfPs) to manufacture cefiderocol to treat bacterial infections Clinton Health Access Initiative

Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps - ACS Publications

Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps ACS Publications

Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics - The Lancet

Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics The Lancet

Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action - The Lancet

Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action The Lancet

Challenges and Opportunities with Antibiotic Discovery and Exploratory Research - ACS Publications

Challenges and Opportunities with Antibiotic Discovery and Exploratory Research ACS Publications

What urologists can expect in Q4 of 2025 - Urology Times

What urologists can expect in Q4 of 2025 Urology Times

GARDP and Orchid Pharma enter antibiotic sublicense deal - Pharmaceutical Technology

GARDP and Orchid Pharma enter antibiotic sublicense deal Pharmaceutical Technology

Enhanced antibacterial efficacy of Lysinibacillus fusiformis-mediated bimetallic silver-gold nanocomposites against multidrug-resistant chronic wound bacterial pathogens - ScienceDirect.com

Enhanced antibacterial efficacy of Lysinibacillus fusiformis-mediated bimetallic silver-gold nanocomposites against multidrug-resistant chronic wound bacterial pathogens ScienceDirect.com

Capturing Global, Predicting Local for Controlling Antimicrobial Resistance: a retrospective multivariable analysis - medRxiv

Capturing Global, Predicting Local for Controlling Antimicrobial Resistance: a retrospective multivariable analysis medRxiv

[Registration Closed] HGPI-Keio University Joint Lecture “Rethinking Actions Against AMR: From Research to Policy, From Japan to the World” (October 1, 2025) - 日本医療政策機構

[Registration Closed] HGPI-Keio University Joint Lecture “Rethinking Actions Against AMR: From Research to Policy, From Japan to the World” (October 1, 2025) 日本医療政策機構

Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight? - BioMed Central

Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight? BioMed Central

GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 - Health Policy Watch

GARDP To Develop & Deliver 5 New Treatments For Antibiotic Resistant Infections By 2025 Health Policy Watch

Here’s how we could stop antimicrobial resistance becoming the next pandemic - Gavi, the Vaccine Alliance

Here’s how we could stop antimicrobial resistance becoming the next pandemic Gavi, the Vaccine Alliance

[Event Report] HGPI-Keio University Joint Lecture “Rethinking Actions Against AMR: From Research to Policy, From Japan to the World” (October 1, 2025) - 日本医療政策機構

[Event Report] HGPI-Keio University Joint Lecture “Rethinking Actions Against AMR: From Research to Policy, From Japan to the World” (October 1, 2025) 日本医療政策機構

Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: Combined retrospective analyses of two real-world databases and in vitro data - medRxiv

Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: Combined retrospective analyses of two real-world databases and in vitro data medRxiv

The drugs don't work: WHO's role in advancing new antibiotics - The Lancet

The drugs don't work: WHO's role in advancing new antibiotics The Lancet

Investigational antibiotic zoliflodacin promising treatment of uncomplicated gonorrhea - Medical Dialogues

Investigational antibiotic zoliflodacin promising treatment of uncomplicated gonorrhea Medical Dialogues

GARDP commits $20 million for Bugworks’ molecule to fight MDR bacteria - The Hindu

GARDP commits $20 million for Bugworks’ molecule to fight MDR bacteria The Hindu

GARDP collaborates with ICMR to initiate study on status of antibiotic-resistant infections in hospitals - financialexpress.com

GARDP collaborates with ICMR to initiate study on status of antibiotic-resistant infections in hospitals financialexpress.com

Orchid Pharma to make cefiderocol for GARDP - suryaa.com

Orchid Pharma to make cefiderocol for GARDP suryaa.com

Global Antibiotic Research & Development Partnership (GARDP) - Vajiram & Ravi

Global Antibiotic Research & Development Partnership (GARDP) Vajiram & Ravi

Orchid Pharma to make cefiderocol for GARDP - dtnext

Orchid Pharma to make cefiderocol for GARDP dtnext

Top Global Antibiotic R&D Partnership (Gardp) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant